Exact Sciences, the Madison-based biotech company, is expanding its cancer detection portfolio this year with two recently launched tests and another set for the coming months.
Cologuard Plus, an updated version of the company’s flagship colorectal cancer screening test, came out in March. Oncodetect, a blood test for detecting molecular residual disease, followed in May.
In the second half of the year, the company plans to launch Cancerguard EX, a test to screen for multiple cancers that begin in an organ, such as lung cancer, stomach cancer or ovarian cancer…